Breaking Finance News

ValuEngine downgraded Cempra Inc (NASDAQ:CEMP) to Strong Sell in a statement released earlier today.

Only yesterday Cempra Inc (NASDAQ:CEMP) traded -3.45% lower at $4.00. The company’s 50-day average is $3.14 and its two hundred day average is $3.67. With the last close up -23.78% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. Trading volume was down over the average, with 667,281 shares of CEMP changing hands under the typical 804,606

ValuEngine has downgraded Cempra Inc (NASDAQ:CEMP) to Strong Sell in a statement released on 6/02/2017.

Performance Chart

Cempra Inc (NASDAQ:CEMP)

With a total market value of $0, Cempra Inc has with a 52 week low of $2.55 and a 52 week high of $24.48 .

A total of 12 equity analysts have released a research note on CEMP. Five firms rating the stock a strong buy, 6 firms rating the stock a buy, two analysts rating the company a hold, zero brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $38.75.

Brief Synopsis On Cempra Inc (NASDAQ:CEMP)

Cempra, Inc. is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus, coagulase negative staphylococci and other gram-positive bacteria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.